Supplemental Agreement and First Amendment to License Agreement regarding NEFECONTM between Calliditas Therapeutics AB (Publ) and Everest Medicines II LimitedSupplemental Agreement • April 27th, 2022 • Calliditas Therapeutics AB • Pharmaceutical preparations
Contract Type FiledApril 27th, 2022 Company IndustryThis SUPPLEMENTAL AGREEMENT AND FIRST AMENDMENT TO THE LICENSE AGREEMENT REGARDING NEFECONTM (this “First Amendment”) is made and entered into by and between Calliditas Therapeutics AB (Publ), corp. reg. no. 556659-9766, with a registered office at PO Box 70351, SE-107 24 Stockholm, Sweden (“Licensor” or “Calliditas”), and Everest Medicines II Limited, an exempted company organized and existing under the laws of Cayman Islands, with a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 (“Licensee”). Licensor and Licensee may be referred herein individually as a “Party”, and collectively as the “Parties”.